Neovasc (NSDQ:NVCN) today released 1st quarter 2016 earnings that fell short of the Street’s expectations in revenue and losses per share, though analysts remained optimistic about Tiara trial enrollment numbers. The company reported losses of $7.6 million, or 16¢ per share, on sales of $2 million for the 3 months ended March 31. That amounts to […]
Neovasc (NSDQ:NVCN) shares are up today after the replacement heart valve maker posted its 4th-quarter and 2015 results yesterday, despite wider Q4 losses on a nearly -25% sales decline. Vancouver-based Neovasc, which is looking to be the 1st to market with a transcatheter mitral valve implant, put up losses of -$7.4 million, or -11 per share, on sales […]
Neovasc (NSDQ:NVCN) said today that it won approval from the FDA to expand a clinical trial of its Tiara transcatheter mitral valve implant to include a larger valve size. Vancouver-based Neovasc said the federal safety watchdog approved the use of the 40mm Tiara device in its 30-patient Tiara-I early feasibility study, which was already approved […]
Neovasc (NASDAQ:NVCN) reported 2nd quarter sales ahead of estimates, though down from 2014 and marked by growing losses, but rallied around the progress of its Tiara transcatheter mitral valve implant feasibility trial. The company’s 30-patient Tiara 1 trial has 2 study patients implanted, in addition to 5 patients implanted through compassionate use regulations. Of the 3 compassionate […]
UPDATED June 6, 2014, with comment from Neovasc.